ATE252911T1 - Behandlung von störungen mittels interleukin-9 - Google Patents

Behandlung von störungen mittels interleukin-9

Info

Publication number
ATE252911T1
ATE252911T1 AT97939680T AT97939680T ATE252911T1 AT E252911 T1 ATE252911 T1 AT E252911T1 AT 97939680 T AT97939680 T AT 97939680T AT 97939680 T AT97939680 T AT 97939680T AT E252911 T1 ATE252911 T1 AT E252911T1
Authority
AT
Austria
Prior art keywords
treatment
interleukin
disorders
thyroiditis
subject
Prior art date
Application number
AT97939680T
Other languages
English (en)
Inventor
Jean-Christophe Renauld
Mary-Christine Many
Francois Huaux
Dominique Lison
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE252911T1 publication Critical patent/ATE252911T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/206—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97939680T 1996-08-30 1997-08-29 Behandlung von störungen mittels interleukin-9 ATE252911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/706,302 US5830454A (en) 1996-08-30 1996-08-30 Method for treating cell mediated autoimmune disorders using interleukin-9
PCT/US1997/015264 WO1998008545A1 (en) 1996-08-30 1997-08-29 Methods for treating disorders by using interleukin-9 and its antagonists

Publications (1)

Publication Number Publication Date
ATE252911T1 true ATE252911T1 (de) 2003-11-15

Family

ID=24837006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939680T ATE252911T1 (de) 1996-08-30 1997-08-29 Behandlung von störungen mittels interleukin-9

Country Status (11)

Country Link
US (2) US5830454A (de)
EP (1) EP1007093B1 (de)
JP (1) JP2000517322A (de)
AT (1) ATE252911T1 (de)
AU (1) AU721908B2 (de)
CA (1) CA2263935A1 (de)
DE (1) DE69725897T2 (de)
DK (1) DK1007093T3 (de)
ES (1) ES2210569T3 (de)
PT (1) PT1007093E (de)
WO (1) WO1998008545A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
US6328955B1 (en) * 2000-01-25 2001-12-11 Ludwig Institute For Cancer Research Method for regulating IL-10 with IL-9, and applications thereof
US6586336B2 (en) 2001-08-31 2003-07-01 Oriol, Inc. Chemical-mechanical-polishing station
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0526000D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Cytokine receptor
WO2012129394A2 (en) 2011-03-22 2012-09-27 Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5414071A (en) * 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
IE910916A1 (en) * 1990-03-23 1991-09-25 Ludwig Inst For Cancer Res Gsf Method for enhanced growth and proliferation of mast cells
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
DE69635305T2 (de) * 1995-08-24 2006-07-06 Genaera Corp. Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9

Also Published As

Publication number Publication date
EP1007093B1 (de) 2003-10-29
WO1998008545A1 (en) 1998-03-05
PT1007093E (pt) 2004-03-31
US5935929A (en) 1999-08-10
AU4171297A (en) 1998-03-19
JP2000517322A (ja) 2000-12-26
ES2210569T3 (es) 2004-07-01
DE69725897D1 (de) 2003-12-04
EP1007093A1 (de) 2000-06-14
EP1007093A4 (de) 2000-11-08
AU721908B2 (en) 2000-07-20
CA2263935A1 (en) 1998-03-05
US5830454A (en) 1998-11-03
DE69725897T2 (de) 2004-08-26
DK1007093T3 (da) 2004-01-26

Similar Documents

Publication Publication Date Title
ATE209483T1 (de) Behandlung von multipler sklerose
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE250412T1 (de) Muskarinische antagonisten zur behandlung von presbyopie
BR9709068A (pt) Processo de tratamento.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE252911T1 (de) Behandlung von störungen mittels interleukin-9
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
EA199800859A1 (ru) Способ лечения при ядовитых укусах и ужалениях
EP0255224A3 (de) Cyclische und verbrückt cyclische Analoge von Somatostatin, verwendbar als analgetische Arzneimittel
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
RU93057223A (ru) Способ лечения параличей и парезов
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
SU1662585A1 (ru) Способ лечени заболеваний головного мозга, сопровождающихс сосудистыми нарушени ми
RU95116393A (ru) Способ лечения заболеваний спинного мозга
RU96115416A (ru) Способ лечения больных с частичной атрофией зрительных нервов
RU94020373A (ru) Способ лечения больных ревматоидным артритом
RU93007819A (ru) Способ лечения больных с заболеваниями цнс и устройство для осуществления способа
EA199700102A1 (ru) Способ "вигесол" коррекции энергетического состояния организма человека
RU93039401A (ru) Электрострессопсихотерапия

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007093

Country of ref document: EP

REN Ceased due to non-payment of the annual fee